USP22 and lung carcinoma: Importantly, we observe that all anti–PD-1 responding patients with lung cancer show statistically significant lower USP22 expression levels, which are reversibly associated with increased tumoral HLA-I (β2M) expression and CD8+ T cell infiltration.